Get the Stockscreener App
1.6693
0.83%
-0.0007
Coherus Oncology Inc stock is traded at $1.6693, with a volume of 219.10K.
It is down -0.83% in the last 24 hours and up +28.39% over the past month.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
See More
Previous Close:
$1.67
Open:
$1.66
24h Volume:
219.10K
Relative Volume:
0.16
Market Cap:
$129.54M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.642
EPS:
-2.6
Net Cash Flow:
$-175.17M
1W Performance:
-2.58%
1M Performance:
+28.39%
6M Performance:
+98.13%
1Y Performance:
+67.26%
1-Day Range:
$1.63
$1.6999
1-Week Range:
$1.63
$1.89
52-Week Range:
$0.6603
$2.43
Coherus Oncology Inc Stock (CHRS) Company Profile
Name
Coherus Oncology Inc
Sector
Industry
Phone
(650) 649-3530
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.6693 | 194.10M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.02 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.75 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Upgrade | Maxim Group | Hold → Buy |
| Aug-16-24 | Downgrade | UBS | Buy → Neutral |
| Nov-17-23 | Initiated | Robert W. Baird | Outperform |
| Nov-08-23 | Downgrade | Maxim Group | Buy → Hold |
| Jul-24-23 | Initiated | Citigroup | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Mar-28-23 | Upgrade | UBS | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Neutral |
| Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-16-20 | Initiated | BofA Securities | Neutral |
| Apr-17-20 | Initiated | SunTrust | Buy |
| Aug-13-19 | Initiated | Mizuho | Buy |
| Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-02-19 | Reiterated | Maxim Group | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-07-19 | Initiated | H.C. Wainwright | Buy |
| Aug-28-18 | Initiated | H.C. Wainwright | Buy |
| Mar-09-18 | Reiterated | Maxim Group | Buy |
| Aug-08-17 | Reiterated | JP Morgan | Overweight |
| Jun-13-17 | Reiterated | Maxim Group | Buy |
| May-05-17 | Initiated | BMO Capital Markets | Outperform |
| Oct-19-16 | Initiated | Robert W. Baird | Outperform |
| Sep-07-16 | Initiated | Maxim Group | Buy |
| Jul-27-16 | Initiated | Citigroup | Buy |
| Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Oncology Inc Stock (CHRS) Latest News
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
How strong dollar benefits Coherus Oncology Inc. (8C5) stockJuly 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com
Why Coherus Oncology Inc. (8C5) stock is trending on social mediaJuly 2025 Market Mood & High Accuracy Trade Signal Alerts - newser.com
Published on: 2025-10-06 04:13:27 - newser.com
How Coherus Oncology Inc. (8C5) stock reacts to monetary easingJuly 2025 Review & Low Drawdown Trading Strategies - newser.com
Published on: 2025-10-05 03:27:37 - newser.com
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Coherus Oncology Announces Upcoming Presentation of CHS-114 Data at SITC 2025 Annual Meeting - Quiver Quantitative
Coherus Oncology Announces Poster Presentation at the 40th - GlobeNewswire
Selective intratumoral Treg depletion — Coherus Oncology's CHS-114 at SITC Nov 8; Webinar Oct 22 - Stock Titan
Published on: 2025-10-03 06:30:25 - newser.com
Will Coherus BioSciences Inc. outperform the marketMarket Risk Analysis & Low Risk High Reward Trade Ideas - newser.com
Published on: 2025-10-03 05:08:55 - newser.com
What technical patterns form on Coherus Oncology Inc. (8C5) stock charts2025 Dividend Review & Accurate Buy Signal Alerts - newser.com
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Coherus BioSciences at UBS Virtual Oncology Day: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Coherus Oncology: Five Readouts Or More Possible In 2026 - Seeking Alpha
Published on: 2025-10-01 05:00:35 - newser.com
What dividend safety rating applies to Coherus Oncology Inc. (8C5) stockMarket Risk Summary & Weekly Momentum Stock Picks - newser.com
What analysts say about Coherus Oncology Inc 8C5 stockStock Screening Results & Free Gain Edge With Data - earlytimes.in
Coherus Oncology Inc 8C5 Stock Analysis and ForecastEconomic Indicators Overview & Small Budget Wealth Tips - Early Times
Strs Ohio Acquires Shares of 324,000 Coherus Oncology, Inc. $CHRS - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Passes Above 200 Day Moving AverageHere's Why - MarketBeat
3 Promising Penny Stocks With Market Caps At Least $100M - simplywall.st
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Coherus Oncology Inc (NASDAQ: CHRS) Rises 7.09% In Recent Trading, What’s Next? - stocksregister.com
Coherus Oncology, Inc. $CHRS Shares Sold by State of Wyoming - Defense World
Coherus BioSciences at H.C. Wainwright: Strategic Shift to Immuno-Oncology - Investing.com
Coherus BioSciences at H.C. Wainwright: Strategic Shift to Immuno-Oncology By Investing.com - Investing.com Canada
Maxim Group Upgrades Coherus Oncology (NASDAQ:CHRS) to "Buy" - MarketBeat
Coherus BioSciences at Baird Conference: Oncology Focus Amid Asset Sales - Investing.com
Coherus Biosciences Regains Nasdaq Compliance - The Globe and Mail
Coherus Oncology regains Nasdaq compliance after meeting minimum bid price - Investing.com
Coherus Oncology (NASDAQ:CHRS) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Rating Upgraded by Maxim Group - Defense World
Maxim Group Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛
Maxim Group upgrades Coherus Biosciences stock to Buy on oncology pivot By Investing.com - Investing.com South Africa
Maxim Group upgrades Coherus Biosciences stock to Buy on oncology pivot - Investing.com Canada
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Coherus Oncology (CHRS) Receives Upgrade from Maxim Group | CHRS Stock News - GuruFocus
Maxim Group Upgrades Coherus Oncology to Buy, Sets PT at $4 - AInvest
RSI Reset May Fuel Rebound in Coherus BioSciences Inc.July 2025 Sector Moves & Technical Pattern Recognition Alerts - beatles.ru
Coherus Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Leader Coherus Oncology Sets Major Conference Schedule: Baird, Wainwright, and UBS Events - Stock Titan
Coherus Oncology Inc Stock (CHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):